Recently, it has been shown that genes involved in embryonic development, pluri/multipotency, and cell reprogramming such as VENTX/NANOG and POU5/OCT4 are abnormally reactivated in late cancer stages, where acting as Epigenetic Drivers (Epi-Drivers) they empower cancer cells with cancer stem cell (CSCs) features, resistance to anticancer therapies, and potential for cancer recurrence/relapse (Vogelstein et al., 2013; Hepburn et al., 2019; Villodre et al., 2016; Ducos et al., 2022; Rawat et al., 2010; Laise, 2022; Park et al., 2021). Here, VENTX is linked to cancer.